Extracellular vesicles in non-small cell lung cancer stemness and clinical applications

Non-small cell lung carcinoma (NSCLC) accounts for 85% of lung cancers, the leading cause of cancer associated deaths in the US and worldwide. Within NSCLC tumors, there is a subpopulation of cancer cells termed cancer stem cells (CSCs) which exhibit stem-like properties that drive NSCLC progression...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2024-05, Vol.15, p.1369356-1369356
Main Authors: Pandya, Prita, Al-Qasrawi, Dania S, Klinge, Skyeler, Justilien, Verline
Format: Article
Language:English
Subjects:
Animals
biomarkers
Biomarkers, Tumor - metabolism
cancer stem cells
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Cell Communication
extracellular vesicles
Extracellular Vesicles - metabolism
Humans
Immunology
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
metastasis
Neoplastic Stem Cells - metabolism
Neoplastic Stem Cells - pathology
non-small cell lung cancer
Tumor Microenvironment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Non-small cell lung carcinoma (NSCLC) accounts for 85% of lung cancers, the leading cause of cancer associated deaths in the US and worldwide. Within NSCLC tumors, there is a subpopulation of cancer cells termed cancer stem cells (CSCs) which exhibit stem-like properties that drive NSCLC progression, metastasis, relapse, and therapeutic resistance. Extracellular vesicles (EVs) are membrane-bound nanoparticles secreted by cells that carry vital messages for short- and long-range intercellular communication. Numerous studies have implicated NSCLC CSC-derived EVs in the factors associated with NSCLC lethality. In this review, we have discussed mechanisms of EV-directed cross-talk between CSCs and cells of the tumor microenvironment that promote stemness, tumor progression and metastasis in NSCLC. The mechanistic studies discussed herein have provided insights for developing novel NSCLC diagnostic and prognostic biomarkers and strategies to therapeutically target the NSCLC CSC niche.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1369356